MedTrace Logo

Advanced Data-Aided Medicine Part Lung Cancer

NCT05783024 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-05-10

No results posted yet for this study

Summary

Developing and validating an AI model that supports physicians in their decision process for treating lung cancer patients. This AI model needs to predict the probability of (the evolution of) the outcomes, based on clinical data and a simulated lung cancer treatment plan. The outcome probabilities can be evaluated with different treatment plans to identify the optimal plan. Initially, the input data will be a limited set of selected features such as general patient information, tumour characteristics, laboratory measurement results, comorbidities and treatments. Finally, the goal is to use a deep patient as input to the models.This deep patient is an AI model on its own, trained on hospital data, as described in secondary objectives.

Conditions

Interventions

OTHER

Data collection

retrospective data collection

Sponsors & Collaborators

  • AZ Delta

    lead OTHER

Principal Investigators

  • Ingel Demedts, MD · AZ Delta

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-27
Primary Completion
2024-09-27
Completion
2024-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05783024 on ClinicalTrials.gov